PubMed · 41601157
Human Epidermal Growth Factor Receptor-2 positive metastatic salivary duct carcinoma with remarkable response to targeted therapy: a case report and therapeutic implications.
Abstract
Salivary duct carcinoma (SDC) is a rare and highly aggressive malignancy that frequently overexpresses Human Epidermal Growth Factor Receptor 2 (HER2). Despite the increasing recognition of HER2-targeted strategies, evidence remains limited and largely derived from small trials and case series. We report the case of a middle-aged man with HER2-positive metastatic SDC who achieved near-complete pathologic and radiological response to trastuzumab and docetaxel, enabling surgical resection for locoregional control. This case highlights the role of anti-HER2 therapy as a first-line strategy in SDC and underscores the importance of individualized management plans integrating systemic treatment and locoregional measures.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Clara Rodrigo Juan, Carla Climent Vicente, Francisco Xavier Avilés Jurado, Noemí Bartolomé Cerdà, Joan Lop Gros, Manuel Mazariegos Rubi. 2026-01-22. Human Epidermal Growth Factor Receptor-2 positive metastatic salivary duct carcinoma with remarkable response to targeted therapy: a case report and therapeutic implications.. https://doi.org/10.1097/cad.0000000000001814
Cite the original work for its findings. Save a collection to share your selection of sources.